期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 55, 期 5, 页码 S1-S13出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2009.10.056
关键词
Tumor lysis syndrome; hematologic malignancy; acute kidney injury; hyperuricemia; prevention
资金
- sanofi-aventis
- Quintiles Medical Education
Tumor lysis syndrome (TLS) describes a constellation of biochemical and clinical abnormalities resulting from rapid and massive tumor cell death. TLS is frequently associated with hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia that may lead to serious clinical complications, including acute kidney injury and cardiac arrest. Identification of tumor-and patient-specific risk factors for TLS and early recognition of laboratory and clinical TLS based on established criteria are essential for preventing TLS and forestalling acute kidney injury. Early collaboration between oncologists and nephrologists will help improve assessment of patients' kidney function and risk factors, paving the way for timely and efficacious interventions. Am J Kidney Dis 55(S3):S1-S13. (C) 2010 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据